Betta's ensartinib shows promise as postoperative adjuvant therapy for ALK-positive NSCLC, potentially expanding its oncology portfolio after NEJM publication
Executive summary: Betta's ensartinib adjuvant therapy study (ELEVATE) for ALK‑positive NSCLC stage IB–IIIB was published in the New England Journal of Medicine on July 8, 2026. The results provide the first robust evidence that an ALK inhibitor can reduce recurrence after surgery in early‑stage ALK‑positive NSCLC, potentially creating a new adjuvant indication and expanding the drug's market.
Who is involved: Betta Pharmaceuticals (sponsor), the ELEVATE study investigators, patients with ALK‑positive NSCLC, and the New England Journal of Medicine editorial team.
Likely next: Betta may prepare regulatory submissions for an adjuvant indication, present detailed results at upcoming oncology conferences (e.g., ASCO 2026), and discuss label expansion with health‑technology assessment bodies.
The study of Betta's ensartinib as postoperative adjuvant therapy for stage IB–IIIB ALK-positive non-small cell lung cancer, known as the ELEVATE study, was published online in full in The New England Journal of Medicine on July 8, 2026. The publication provides peer‑validated efficacy and safety data for ensartinib in the adjuvant setting, a context where few ALK‑targeted agents have demonstrated benefit. This milestone could influence future treatment guidelines and regulatory submissions for ensartinib in early‑stage lung cancer.
Timeline
- — Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine (PR Newswire)
Analysis — what this means
Sectors affected
- ALK‑positive non‑small cell lung cancer adjuvant therapy
Historical parallels
- FDA approval of osimertinib as adjuvant therapy for EGFR‑mutated NSCLC based on the ADAURA trial (2020)
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped